Galectin-3 testing: Validity of a novel automated assay in heart failure patients with reduced ejection fraction

Galectin-3 testing: Validity of a novel automated assay in heart failure patients with reduced ejection fraction

Circulating levels of galectin-3 (Gal-3), a marker of cardiac fibrosis and remodeling, contribute to the risk stratification of patients with heart failure (HF). The aim of our study was to determine the analytical validity and clinical validity of a novel automated Gal-3 assay in HF patients with r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinica chimica acta 2014-02, Vol.429, p.189-193
Hauptverfasser: Gruson, D., Mancini, M., Ahn, S.A., Rousseau, M.F.
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Automation
Biomarkers
Blood Chemical Analysis - methods
BNP
Female
Galectin 3 - blood
Galectin-3
Heart failure
Heart Failure - blood
Heart Failure - physiopathology
Humans
Male
Middle Aged
NT-proBNP
Prognosis
Risk Assessment
Stroke Volume
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Circulating levels of galectin-3 (Gal-3), a marker of cardiac fibrosis and remodeling, contribute to the risk stratification of patients with heart failure (HF). The aim of our study was to determine the analytical validity and clinical validity of a novel automated Gal-3 assay in HF patients with reduced ejection fraction. We showed an excellent agreement between the VIDAS® Gal-3 automated assay and the ELISA reference method (r=0.90, p
ISSN:0009-8981
1873-3492
DOI:10.1016/j.cca.2013.12.017